Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. PFSCF


Primary Symbol: LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Bullboard Posts
Post by barcodewhizon Dec 20, 2004 4:38pm
126 Views
Post# 8339002

reckless coverage by Dundee

reckless coverage by Dundee I am actually amazed that someone can get away with printing the uninformed crap that David Martin puts out on Prometic. Its just unbelievable. He clearly has some kind of an axe to grind. For an MBA PhD, its incredible that he uses such shallow assesment of the situation. He really is doing a disservice to Dundee clients. DO YOUR DAMN HOMEWORK MARTIN you idiot If you can combine an oral dose of 1402 with a lower dose of EPO and close to double the effect on reticulocytes with LOWER COST and a potentially expanded patient base in a $10 Billion dollar market.... do you think there potentially may be a little demand for a compound like this amongst big pharma .... ? Its also quite commonly known that effective Dosages in Healthy trials is considerably different (higher)than Dosages in patient populations.... the fact that he is attributing a "higher risk to developent of the compound" at a time where we have just established a considerably lower risk because of both safety and BETTER than expected efficacy in healthy trials... ABSOLUTELY UNBELIEVABLE
Bullboard Posts